A Phase IIA Multicenter Evaluation of the Safety and Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Patients With Relapsed Stage IIIB OR IV Non Small Cell Lung Cancer

NCT00034164 Phase 2 COMPLETED

Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with relapsed stage IIIB or IV non small cell lung cancer.

Details

Lead sponsor	Achieve Life Sciences
Phase	Phase 2
Status	COMPLETED
Enrolment	52
Start date	2002-04
Completion	2007-09

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

• S-8184 Paclitaxel Injectable Emulsion

Primary outcomes

• To determine the objective response rate — After all patients completed therapy

Countries

Russia